$20.00
+1.8%Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. Bicara Therapeutics Inc. is a subsidiary of Biocon Limited.
Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation
Base year metrics used for projections
Forecast period and terminal assumptions
Calculation flow from present value to intrinsic value per share
Operating Cash Flow - Maintenance CapEx = Owner Earnings
| Metric | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | Year 6 | Year 7 | Year 8 | Year 9 | Year 10 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$60.7M | -$34.5M | -$19.6M | -$11.2M | -$6.3M | -$3.6M | -$2.0M | -$1.2M | -$661.8K | -$376.2K |
| Maintenance CapEx | -$31.8K | -$18.1K | -$10.3K | -$5.8K | -$3.3K | -$1.9K | -$1.1K | -$610 | -$347 | -$197 |
| Owner Earnings | -$60.8M | -$34.5M | -$19.6M | -$11.2M | -$6.3M | -$3.6M | -$2.0M | -$1.2M | -$662.1K | -$376.4K |
| Discount Factor | 0.926 | 0.857 | 0.794 | 0.735 | 0.681 | 0.630 | 0.583 | 0.540 | 0.500 | 0.463 |
| Present Value | -$56.3M | -$29.6M | -$15.6M | -$8.2M | -$4.3M | -$2.3M | -$1.2M | -$629.3K | -$331.2K | -$174.3K |
Continue your BCAX research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.